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Purpose: To compare the efficacy of posterior sub-Tenon’s
capsule triamcinolone acetonide injection combined with
modified grid macular photocoagulation (PSTI + MP) with
intravitreal triamcinolone acetonide (IVTA) injection in the
treatment of diffuse diabetic macular edema (DME). Materials
and Methods: Forty eyes of 33 patients with diffuse DME were
randomly allocated into either PSTI +MP (20 eyes) or IVTA
(20 eyes). Best corrected visual acuity (VA) and foveal
thickness were measured. Results: The ETDRS scores at
baseline were 25.2 ± 13.6 (mean ± SD) letters in the PSTI + MP
group, whereas 21.7 ± 16.3 letters in the IVTA group. The
ETDRS scores improved by 33.2 ± 15.9, 34.7 ± 16.6 and 30.9
± 19.0 letters in the PSTI + MP group whereas by 30.9 ± 15.4,
30.1 ± 17.9 and 31.5 ± 15.0 letters in the IVTA group at 1, 3,
and 6 months after the treatments, respectively. The VA improved
significantly at 1 month and 3 months after both treatments
(all p < 0.02, paired t-test). The VA improvements were no
longer significant at 6 months in either group. There were no
statistically significant differences at any time points between
the 2 groups (all p> 0.05, Student’s t-test). The foveal thicknesses
at baseline and 1, 3, and 6 months after the treatments were
382.8 ± 148.3, 309.1 ± 131.3, 319.3 ± 93.3, 340.4 ± 123.5 mμ
(mean ± SD) in the PSTI + MP group vs. 369.1 ± 123.1, 241.4
± 52.3, 277.5 ± 137.4, 290.2 ± 127.9 mμ in the IVTA group,
respectively. Pairwise comparisons revealed significant decrease
in foveal thickness at 1 month (p = 0.01, paired t-test) for the
PSTI + MP group, and at both 1 month (p < 0.001) and 3
months (p = 0.016) for the IVTA group. There were no
statistically significant differences at any time points between
the 2 groups (all p > 0.05, Student’s t-test). In contrast to the
PSTI + MP group, where no complications were noted, the
elevation of intra-ocular pressure in 3 of 20 eyes (15%) and
a significant increase in average cataract grading were observed
in the IVTA group. Conclusion: PSTI +MP treatment provides
significant improvement of vision in patients with diffuse DME
over 3 months, and achieves outcomes comparable to those
after IVTA treatment, however, with fewer complications.
Key Words: Diabetic macular edema, combined treatment, in-
travitreal triamcinolone injection, posterior sub-Tenon triam-
cinolone injection
INTRODUCTION
Diabetic macular edema (DME) is the major
cause of visual impairment in diabetic patients.
1
Based on the observations of the Early Treatment
Diabetic Retinopathy Study (ETDRS) Group, focal/
grid laser photocoagulation has been the accepted
standard care for DME. However, only 17% of eyes
showed any improvement in visual acuity (VA),
and less than 3% had visual improvements of three
or more ETDRS lines after laser treatments.2-4
Moreover, a significant number of patients with
DME, especially DME of the diffuse type, remain
refractory to focal or grid laser treatments, and this
has driven many investigators to seek alternative
treatments for the management of DME.
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Among alternative treatments currently under
investigation, triamcinolone acetonide has been
reported to be efficacious when administered
either by the intravitreal route or a posterior sub-
Tenon's route in cases of diffuse DME refractory
to laser treatment.5-13 A previous report has shown,
however, that intravitreal triamcinolone acetonide
(IVTA) injection was more effective than posterior
sub-Tenon injection of triamcinolone acetonide in
the management of DME.14 Several recent reports
demonstrated that PSTI was as effective as IVTA
and could be accepted as a valid alternative to
intravitreal injections.15,16 Grid treatment applied
to areas of diffuse macular edema substantially
reduces the risk of visual loss in eyes with DME.10,13
Thus, we hypothesized that grid laser macular
photocoagulation might have an additive or syner-
gistic therapeutic effect on posterior sub-Tenon
triamcinolone injection.
In the current study, we prospectively inves-
tigated the efficacy and safety of IVTA treatment
and posterior sub-Tenon triamcinolone injection
combined with modified grid laser photocoagu-
lation (PSTI + MP) in the management of diffuse
DME.
MATERIALS AND METHODS
The study was a prospective, randomized clini-
cal trial conducted at the Yonsei University Eye
and Ear, Nose, and Throat Hospital (Korea) vitreo-
retinal service. The study followed the tenets of
Declaration of Helsinki and was approved by the
local Institutional Review Board. Informed consent
was obtained from every patient after explanation
of the nature and possible consequences of the
study. Forty eyes of 33 patients with diffuse DME
who visited our clinic from June 2005 to November
2005 were included in the study.
Patients
Patients were included in the study if they had
DME arising from diabetic retinopathy, provided
that the DME was of clinical significance by the
ETDRS test, and also if they had generalized break-
down of the inner blood-retina barrier, as docu-
mented by diffuse fluorescein leakage on angio-
graphy and diffuse thickening of the retina, in-
volving the foveal center and most of the macular
area, on optical coherence tomography (OCT). The
exclusion criteria were (1) a prior history of
vitrectomy, (2) intraocular surgery other than vit-
rectomy, including cataract extraction, within the
6 months prior to potential enrolment, (3) laser
treatments including panretinal photocoagulation,
posterior capsulotomy, or focal/grid macular
photocoagulation within the 6 months prior to
potential enrolment, (4) presence of ischemic
maculopathy documented on preoperative fluores-
cein angiography, (5) prior history of elevated
intraocular pressure (IOP) secondary to steroid
treatment, (6) history of glaucoma or ocular hyper-
tension, or (7) presence of comorbid ocular con-
ditions that might affect VA.
Ophthalmic examinations to evaluate macular
edema were performed using 90+ diopter non-
contact lens slit lamp biomicroscopy. Fluorescein
angiography, color fundus photography, and
Third Generation OCT (OCT3, instrument from
Stratus Zeiss Humphrey, San Leandro, CA, USA)
were performed by the same experienced masked
ophthalmic technician. For each patient, the best
corrected VA was determined with the ETDRS
chart.17 Foveal thickness was measured by OCT
using the Fast Macular Thickness scan. IOP was
measured using a Goldman applanation tonometer.
Cataract progression was determined according to
the Lens Opacities Classification System III (LOCS
III) grading system.18 Patients were monitored for
potential injection-related and laser-related com-
plications. Examinations were carried out at base-
line and also at 1 month, 3 months, and 6 months
after treatment, and the results were evaluated by
the same masked retinal specialist (HL). The
patients' treatment groups were masked during
follow-up visits.
Surgical procedures
Forty eyes of 33 patients were randomly al-
located into one of two treatment groups by a
permuted block randomization. A total of 20 eyes
received PSTI + MP treatment, and the second
group of 20 eyes received IVTA treatment. After
randomization, treatments were carried out by the
same retinal specialist (HJK).
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The IVTA group received intravitreal injection
of 4 mg/0.1 mL triamcinolone acetonide (40 mg/
ml; Tamceton ; Hanall Pharmaceutical, Seoul,
Korea). The injections were performed using 0.5%
(w/v) proparacaine drops (Alcaine; Alcon Labo-
ratories, Fort Worth, TX, USA) for topical anes-
thesia under sterile conditions. The drug was
injected through the inferotemporal pars plana
using a 30 gauge needle. The appropriate intra-
vitreal localization of the suspension and perfusion
of the optic nerve head were confirmed by indirect
ophthalmoscopy.
Each patient in the PSTI + MP group who re-
ceived a posterior sub-Tenon triamcinolone injec-
tion after macular photocoagulation had been
performed earlier on the same day. We performed
macular grid photocoagulation on spots 100 m inμ
diameter, with width spacings of 1 - 2 burns, an
exposure time of 0.1 - 0.2 sec, and a laser power
of 100 - 150 mW. Grid laser photocoagulation was
performed by placing medium white laser burns
over the entire areas with thicknesses of 350 m,μ
as documented on OCT Fast Macular Thickness
scans. Laser treatment over papillomacular bundles
was avoided. Posterior sub-Tenon triamcinolone
injection was performed after laser photocoa-
gulation. Before injection, 0.5% (w/v) proparacaine
drops were applied and 40 mg of triamcinolone
acetonide (1 mL) was injected with a 25 gauge,
5/8-inch-long needle attached to a tuberculin
syringe. The superotemporal conjunctival fornix
was penetrated with the needle, and the drug was
injected.19
Measurements of primary outcome
The measurements of primary outcome included
best-corrected ETDRS VA scores and foveal thick-
nesses measured by OCT. Each ETDRS VA score
was measured by a masked investigator by deter-
mining the number of letters which a patient was
able to read from the ETDRS charts with correction
for individual refractive errors. The main outcome
measurements were performed at baseline and at
1 month, 3 months, and 6 months after treatments.
Secondary endpoints were complication rates, as
evaluated by IOP measurements, cataract progres-
sion, and injection-related ptosis (measured by the
distance between the reflection from the corneal
apex and the upper eyelid).
Sample size calculation
After considering the results of previous studies
and our preliminary data with intravitreal and
posterior sub-Tenon drug injections for DME, we
concluded that a sample size of at least 18 eyes
per treatment group offered a probability of 80%
for detection of a 35% reduction in macular thick-
ness at the 0.05 significance level (2-sided).5,6 We
estimated 10% follow-up loss of patients during
the study, and therefore our goal was to recruit
20 eyes for each group.
Statistical analyses
Baseline demographic and clinical parameters
were compared between treatment groups using
Student's t-tests for continuous variables and chi-
square tests for categorical variables. The study
endpoints were analyzed using repeated measures
ANOVA, which was adjusted for correlations of
subjects within a group and group/time interac-
tions. Between-group comparisons at each time
point were performed using Student's t-test. In
addition, paired t-tests were utilized to compare
differences between each follow-up time point and
baseline values within each treatment group.
Statistical analyses utilized SPSS 12.0.1 (SPSS
Inc., Chicago, IL, USA) for Windows. The level of
statistical significance was set at p < 0.05. For
within-group comparisons, the significance level
was adjusted to take the number of comparisons to
baseline into account (ɑ = 0.05/3 = 0.0167; Bonfer-
roni's adjustment for multiple comparisons).
RESULTS
The baseline characteristics are listed in Table 1,
there was no statistically significant difference
between the 2 groups. All randomized eyes fol-
lowed assigned treatments to the end of the study.
Early Treatment Diabetic Retinopathy Study score
Repeated measures ANOVA showed a sig
nificant effect on VA with either treatment (p =
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0.03) and over time (p < 0.001). No significant
treatment/time interaction was found (p = 0.53).
Fig. 1 and Table 2 present, the mean changes in
ETDRS scores at baseline and at 1 month, 3 months,
and 6 months after treatment. Within each treat-
ment group, pairwise comparisons revealed signi-
ficant improvements in ETDRS scores after 1 month
and 3 months (all p < 0.016, using the Bonferroni
adjustment; significance level = 0.0167). The VA
improvements were no longer statistically signi-
ficant at 6 months in either group. Between-group
comparisons revealed no significant differences in
changes of ETDRS scores from baseline at any
timepoint.
In patients who had visual improvement, 10 of
20 eyes (50%) in the PSTI + MP group and 11 of
20 eyes (55%) in the IVTA group showed an
increase of more than one line in ETDRS scores
at 6 months after treatment (p = 0.75).
Table 1. Baseline Characteristics
Variable
(n = participants/eyes)
PSTI+MP group
(n = 17/20)
IVTA group
(n = 16/20)
p value
Age, mean ± SD, yrs (range) 62.8 ± 8.3 (51-79) 61.3 ± 9.8 (36 - 76) 0.63*
Gender No. 0.55
Male (%) 7 (41.2) 5 (31.3)
Female (%) 10 (58.8) 11 (68.7)
Duration of diabetes, mean ± SD, yrs 14.5 ± 4.3 14.1 ± 11.3 0.90*
Lens, No. 0.14
Phakic (%) 17 (85) 13 (65)
Pseudophakic (%) 3 (15) 7 (35)
Status of DR 0.19
NPDR (%) 15 (75) 11 (55)
PDR (%) 5 (25) 9 (45)
Prior grid sessions, mean, No. (range) 0.2 (0-1) 0.3 (0 - 1) 0.47
ETDRS score, mean ± SD 25.2 ± 13.6 21.7 ± 16.3 0.47*
IOP, mean ± SD, mmHg 15.5 ± 3.9 14.4 ± 3.2 0.32*
Foveal thickness, mean ± SD, mμ 382.8 ± 148.3 369.1 ± 123.1 0.75*
PSTI + MP, posterior subtenon triamcinolone injection + grid laser macular photocoagulation; IVTA, intravitreal triamcinolone
acetonide injection; DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy;
ETDRS, Early Treatment of Diabetic Retinopathy Study; IOP, intraocular pressure.
*Student t-test.
Pearson 
2
test.
Fig. 1. Changes in mean ETDRS scores after treatments.
ETDRS, Early Treatment Diabetic Retinopathy Study.
PSTI, posterior subtenon triamcinolone injection; IVTA,
intravitreal triamcinolone acetonide injection; ETDRS, Early
Treatment of Diabetic Retinopathy Study
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Foveal thickness
Repeated measures ANOVA showed a signi-
ficant effect of either treatment on mean foveal
thickness (p = 0.01), over time (p < 0.001). No signi-
ficant treatment/time interaction was found (p =
0.56). Fig. 2 and Table 3 present the changes of
mean foveal thicknesses at baseline and at 1 month,
3 months, and 6 months after treatments. Pairwise
comparisons revealed significant improvements in
average foveal thicknesses at 1 month (p = 0.01) for
the PSTI + MP group, and at both 1 month (p <
0.001) and 3 months (p = 0.016) for the IVTA group.
Between-group comparisons revealed no signifi-
cant differences in changes of foveal thicknesses
from the baseline at any timepoint.
Table 2. Changes in ETDRS Score
Time points
(months)
PSTI +MP (n = 20) IVTA (n = 20)
p value
Mean ± SD p value*
Change vs.
baseline ± SD
Mean ± SD p value*
Change vs.
baseline ± SD
0 25.2 ± 13.6 21.7 ± 16.3
1 33.2 ± 15.9 0.002 8.05 ± 7.59 30.9 ± 15.4 < 0.001 9.25 ± 9.71 0.666
3 34.7 ± 16.6 < 0.001 9.50 ± 8.00 30.1 ± 17.9 < 0.001 8.35 ± 9.71 0.685
6 30.9 ± 19.0 0.029 (NS) 5.75 ± 11.43 31.5 ± 15.0 0.037 (NS) 9.80 ± 9.62 0.233
ETDRS, Early Treatment of Diabetic Retinopathy Study; PSTI + MP, posterior subtenon triamcinolone injection + grid laser macular
photocoagulation; IVTA, intravitreal triamcinolone acetonide injection; NS, not significant.
*Baseline vs. follow up measures within a group; paired t-test, significance level 0.0167 (Bonferoni adjustment for multiple
comparisons).
PSTI+MP group vs. IVTA group comparing change vs. baseline values; Student t-test, significance level 0.05.
Table 3. Changes in Foveal Thickness (µm)
Time points
(months)
PSTI +MP (n = 20) IVTA (n = 20)
p value
Mean ± SD p value*
Change vs.
baseline ± SD
Mean ± SD p value*
Change vs.
baseline ± SD
0 382.8 ± 148.3 369.1 ± 123.1
1 309.1 ± 131.3 0.01 73.66 ± 83.25 241.4 ± 52.3 < 0.001 128.45 ± 113.28 0.089
3 319.3 ± 93.3 0.026 (NS) 63.55 ± 107.81 277.5 ± 137.4 0.016 94.90 ± 164.57 0.480
6 340.4 ± 123.5 0.14 42.40 ± 111.42 290.2 ± 127.9 0.11 91.11 ± 188.65 0.330
PSTI + MP, posterior subtenon triamcinolone injection + grid laser macular photocoagulation; IVTA, intravitreal triamcinolone
acetonide injection; NS, not significant.
*Baseline vs. follow up measures within a group; paired t-test, significance level 0.0167 (Bonferoni adjustment for multiple
comparisons).
PSTI + MP group vs. IVTA group comparing change vs. baseline values; Student t-test, significance level 0.05.
Fig. 2. Changes in mean foveal thicknesses after treat-
ments. PSTI, posterior subtenon triamcinolone injection;
IVTA, intravitreal triamcinolone acetonide injection.
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Complications
Fig. 3 and Table 4 present changes of mean IOP
from baseline at 1 month, 3 months, and 6 months
after treatments. Between-group comparisons re-
vealed significant differences in mean IOP changes
at 1 month and 3 months (p = 0.006, p = 0.026,
respectively). Three of 20 (15%) eyes in the IVTA
group developed IOP elevation which exceeded 21
mmHg; and this was controlled with topical anti-
glaucomatous agents. The 3 eyes with elevated IOP
belonged to three different patients. No eye that
received a posterior sub-Tenon injection developed
increased IOP exceeding 21 mmHg.
One of 20 (5%) eyes in the PSTI + MP group
showed a complication of mild ptosis that gradual-
ly improved towards the end of the study. Accor-
ding to the LOCS III scoring system, the average
increases in cataract grading, compared to baseline
values, were 0.62 ± 0.81 (mean ± SD) in the PSTI +
MP group and 1.54 ± 1.33 in the IVTA group; the
latter was significantly higher than the former (p
= 0.043, Student’s t-test). Significant cataract pro-
gression that necessitated cataract surgery was
noted in 1 of 13 (7.7%) phakic eyes in the IVTA
group, but in none of the eyes treated with pos-
terior sub-Tenon injections. The cataract compli-
cation that occurred after IVTA administration was
treated with extracapsular phacoemulsification
and posterior chamber intraocular lens implanta-
tion after the end of the study.
Serious vision-threatening complications, such
as infectious endophthalmitis, vitreous hemor-
rhage, scleral perforation, and retinal detachment,
were not encountered in any study eye.
DISCUSSION
In recent years, application of triamcinolone
Table 4. Changes in IOP
Time points
(months)
PSTI + MP (n = 20) IVTA (n = 20)
p value
Mean ± SD p value*
Change vs.
baseline ± SD
Mean ± SD p value*
Change vs.
baseline ± SD
0 15.50 ± 3.94 14.35 ± 3.22
1 14.50 ± 3.00 0.24 - 1.00 ± 2.90 16.30 ± 3.01 0.14 1.95 ± 3.50 0.006
3 14.25 ± 2.73 0.14 - 1.25 ± 3.09 16.50 ± 5.20 0.09 2.15 ± 5.80 0.026
6 15.35 ± 3.62 0.86 - 0.15 ± 3.48 14.45 ± 2.76 0.85 0.10 ± 3.64 0.826
IOP, intraocular pressure; PSTI + MP, posterior subtenon triamcinolone injection + grid laser macular photocoagulation; IVTA,
intravitreal triamcinolone acetonide injection; NS, not significant.
*Baseline vs. follow up measures within a group; paired t-test, significance level 0.0167 (Bonferoni adjustment for multiple
comparisons).
PSTI+MP group vs. IVTA group comparing change vs. baseline values; Student t-test, significance level 0.05.
Fig. 3. Changes in mean intraocular pressures after treat-
ments. IOP, intraocular pressure; PSTI, posterior subtenon
triamcinolone injection; IVTA, intravitreal triamcinolone
acetonide injection. *IOP was significantly higher in the
IVTA group (p = 0.006 at 1 month, p = 0.026 at 3 months;
Student's t-test).
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acetonide via either an intravitreal or a posterior
sub-Tenon's route has yielded promising results in
the treatment of diffuse DME refractory to laser
treatment.5-9
IVTA has become an increasingly popular
mode of DME treatment, and may be used after
failure of initial laser treatment, or, indeed, instead
of laser treatment as the primary therapeutic
modality in some cases.20,21 The effects of cortico-
steroid delivered by IVTA treatment do not last
longer than 6 months, and recurrence of macular
edema often requires repeated IVTA applica-
tions.5,6 The problem with repeated intraocular
injections of triamcinolone acetonide is that
patients become predisposed to the cumulative
risk of injection-related complications such as
cataract progression, infectious endophthalmitis,
intraocular hemorrhage, retinal detachment, and
glaucoma.5-7,22-24
The advantages of periocular administration of
triamcinolone include lower risks of endophthal-
mitis, cataract progression, and IOP elevation, and
the delivery of triamcinolone via the sub-Tenon
route may offer a safer alternative to intravitreal
injection. However, a previous study compared
treatment results in patients with diffuse DME
after intravitreal injection and sub-Tenon's infu-
sion of triamcinolone acetonide, and suggested
that IVTA treatment might be more effective than
PSTI. On the other hand, some other studies
demonstrated that PSTI would be a valid alterna-
tive to the IVTA.14-16 Thus, we performed modi-
fied grid laser macular photocoagulation on the
same day when PSTI was performed, to take
advantage of additive effects of the laser and drug
treatments previously reported.10,13 We identified
retinal areas with diffuse thickening (prior to
modified grid laser treatment) using the OCT Fast
Macular Thickness scan, because several studies
demonstrated that OCT detects foveal thickening
in DME with a sensitivity better than that offered
by clinical examinations.25-29 Grid laser photocoa-
gulation was performed on the same day as PSTI
treatment in the current study. A question of
whether grid laser treatment applied a few weeks
after steroid administration would result in even
better results should be determined in further
studies.
In our study, both treatment modalities showed
significant treatment effects over a 3 month
period. Although the difference was not statisti-
cally significant, there was a small vision im-
balance at baseline, with the PSTI + MP group
having better vision. As shown in Table 2, the
changes of vision properties from baseline at 1
month and 3 months after treatments were, none-
theless, comparable between the 2 groups. Our
current results seem to contradict a recent report
by the Diabetic Retinopathy Clinical Research
Network.30 These authors reported in a pilot study
that peribulbar triamcinolone with or without
focal photocoagulation was unlikely to be of
substantial benefit in the treatment of mild DME
in patients with VA scores of 20/40 or better. The
apparent disparity may arise because of differ-
ences between the patient groups treated in the 2
studies. In the cited work, patients with mild
DME and relatively good VA values were
included. On the other hand, only 4 of 40 eyes
(10%) had baseline VA values of 20/40 or better
in our current study, and all our patients had
DME of the diffuse type. Because a previous
study showed that worse baseline VA values in
DME patients were associated with better visual
outcomes after IVTA treatment, and that patients
with particularly poor VA scores may benefit
most from the treatments which we employed.31
The duration of the treatment effect seemed to
be longer in the IVTA group, since the mean
ETDRS score began to decline after 3 months in
the PSTI + MP group, but remained relatively
stable to 6 months in the IVTA group, however,
the difference was not statistically significant. By
6 months, the PSTI + MP group showed visual
outcome similar to that of the modified grid laser,
a standard care for diffuse DME, with 5 letters
improvement, indicating that repeated PSTI might
be necessary to maintain optimal treatment out-
comes.
32,33
The IVTA group also showed a longer
mean duration of resolved macular edema, since
a significant change in mean foveal thickness was
apparent 3 months after treatment. This improve-
ment gradually decreased, however, and was no
longer significant by 6 months post-treatment.
Because the functional and tomographical out-
comes in both treatment groups started to decline
by the end of the study, the effect of triamcinolone
delivered by either route appears to be transient.
Eun Jee Chung, et al.962
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Although the interval required between injections
may average longer in IVTA patients under con-
tinuous ophthalmic care, repeated injections would
still be necessary for patients treated with either
modality. It is beyond the scope of the present
study to determine whether IVTA combined with
grid laser photocoagulation would result in a
longer-lasting effect. Further studies on this issue
are warranted.
When complications were considered, we ob-
served a higher mean increase in IOP from baseline
at 1 month and 3 months and a 15% rate of IOP
elevation requiring anti-glaucomatous treatment in
the IVTA group, whereas no eye of the PSTI + MP
group showed a significant elevation of IOP. The
IVTA group also showed significantly higher ave-
rage increase in cataract grading. The frequency of
significant cataract progression requiring surgery
(7.7%) in this study was within the range (0 - 23%)
of previously reported incidences.5-8,34-36 Consider-
ing the relatively short follow-up period of this
study, it should be mentioned that a higher rate
of cataract progression might be observed in the
IVTA group upon longer-term follow-up of patients.
Some limitations of our study are inherent, and
include possible confounding influence of cataract
progression on VA scores in the IVTA group, our
small sample size, limited duration of follow-up,
and a lack of proper control group. We observed
a significant increase in average cataract grading
in the IVTA group, and the mean VA effect in the
IVTA group might be underestimated because of
lens opacification that was not considered to be of
sufficient clinical significance to merit surgery at
the time of observation. Since the modified grid
laser treatment has been a standard care for diffuse
DME and the grid laser photocoagulation combined
with IVTA has also shown promising results,37 a
control group treated with either conventional laser
treatment or IVTA combined with MP would be
necessary to verify the current findings. The cur-
rent study is also limited by the lack of information
regarding the systemic factors that might have
influenced the progression of DME, such as the use
of insulin therapy, oral hypoglycemic drugs and
the status of glycemic control. Further studies with
larger group sizes, proper control group and de-
tailed information regarding systemic factors are
necessary to evaluate the long-term therapeutic
effects, possible side-effects, and appropriate drug
dose, when PSTI + MP is used for the treatment
of DME.
There were seven bilateral DME cases; three in
the PSTI + MP group and four in the IVTA group.
We repeated all statistical analyses, including only
the right eyes of these patients to eliminate any
possible influence of contralateral effects in either
treatment. The results obtained were similar to
those discussed above and therefore, were not
considered any further.
In summary, our pilot study suggests that PSTI
+ MP treatment provides vision improvements in
patients with diffuse DME, similar to those ob-
tainable with IVTA treatment, and that the effects
last for 3 months with fewer complications than
seen in patients receiving IVTA treatment. Further
studies using macular grid photocoagulation with
repeated injections of 40 mg of triamcinolone into
the posterior sub-Tenon's capsule at 3 months
intervals are, therefore, indicated.
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